Baxter International Inc.
BAX
Classifica tra le azioni
#1653
Baxter International Inc., operating globally via its subsidiaries, is a... Baxter International Inc., operating globally via its subsidiaries, is a leading developer and provider of a wide spectrum of healthcare products. The company's comprehensive portfolio includes various dialysis treatments, such as peritoneal and hemodialysis, along with related therapies and services. It also specializes in intravenous (IV) therapies, infusion pumps, administration sets, and devices for drug reconstitution. Further expanding its pharmaceutical offerings, Baxter delivers pre-mixed and oncology drug platforms, inhaled anesthetic agents, critical care products, and pharmacy compounding services. Nutritional support is provided through its parenteral nutrition therapies and associated products. For surgical procedures, the company develops biological products and medical devices vital for achieving hemostasis, tissue sealing, and preventing adhesions. Additionally, Baxter supplies continuous renal replacement therapies (CRRT) and other organ support solutions, primarily tailored for intensive care units. Beyond direct medical supplies, Baxter provides sophisticated connected care solutions, integrating devices, software, communication systems, and other advanced technologies. This includes a range of patient monitoring and diagnostic technologies designed to aid in the diagnosis, treatment, and management of numerous illnesses and conditions, spanning respiratory therapy, cardiology, vision screening, and physical assessment. The surgical suite benefits from its specialized video technologies, operating tables, lights, pendants, precision positioning tools, and various ancillary accessories. The company also offers contracted services to a multitude of pharmaceutical and biopharmaceutical companies. Baxter's products are utilized across diverse healthcare environments, including hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and for home-based patients under medical supervision. Operating in approximately 100 countries, Baxter distributes its extensive product line through a direct sales force, independent distributors, drug wholesalers, and specialty pharmacies or other alternative site providers. The company also holds a collaborative agreement with Celerity Pharmaceutical, LLC, focused on developing generic injectable pre-mixed medications for acute care and oncolytic molecules. Established in 1931, Baxter International Inc. is headquartered in Deerfield, Illinois.
Prezzo delle azioni
$25.03
Ultima sincronizzazione: 2026-10-19
Capitalizzazione di mercato
$12.94B
Variazione (1 giorno)
-1.03%
Variazione (1 anno)
8.19%
Paese
US
Scambia Baxter International Inc. (BAX)
Categoria
Healthcare
Utile per Baxter International Inc. (BAX)
Utile nel Jun 2026 TTM: $-483.00M
Secondo gli ultimi rapporti finanziari di Baxter International Inc., gli utili attuali della società sono $-483.00M. Nel 2024, la società ha registrato un utile di $-289.00M, una diminuzione rispetto a agli utili del 2023, che erano di $242.00M. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Storico degli utili di Baxter International Inc. dal 2000 al 2026
Utile alla fine di ogni anno
| Anno | Utile | Cambia |
|---|---|---|
| 2026 (TTM) | $-483.00M | 1,757.69% |
| 2025 | $-26.00M | -91.00% |
| 2024 | $-289.00M | -219.42% |
| 2023 | $242.00M | -107.45% |
| 2022 | $-3.25B | -319.91% |
| 2021 | $1.48B | 14.32% |
| 2020 | $1.29B | 33.20% |
| 2019 | $970.00M | -40.01% |
| 2018 | $1.62B | 47.00% |
| 2017 | $1.10B | -77.80% |
| 2016 | $4.95B | 1,057.48% |
| 2015 | $428.00M | -12.65% |
| 2014 | $490.00M | 30.67% |
| 2013 | $375.00M | -86.79% |
| 2012 | $2.84B | 1.03% |
| 2011 | $2.81B | 48.62% |
| 2010 | $1.89B | -30.87% |
| 2009 | $2.73B | 11.05% |
| 2008 | $2.46B | 16.46% |
| 2007 | $2.11B | 21.08% |
| 2006 | $1.75B | 20.91% |
| 2005 | $1.44B | 235.81% |
| 2004 | $430.00M | -61.91% |
| 2003 | $1.13B | -18.54% |
| 2002 | $1.39B | 41.57% |
| 2001 | $979.00M | 1.77% |
| 2000 | $962.00M | 0.00% |
Utile per aziende simili o concorrenti
| Azienda | Utile | Differenza negli utili | Il paese |
|---|---|---|---|
| $3.81B | -887.95% |
US
|
|
| $4.11B | -950.69% |
FR
|
|
| - | - |
JP
|
|
| $1.59B | -429.19% |
US
|
|
| - | - |
CH
|
